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PAssociation Between C-Reactive Protein and Recurrence
of Atrial Fibrillation After Successful Electrical Cardioversion
A Meta-Analysis
Tong Liu, MD, PHD,* Guangping Li, MD, PHD,* Lijian Li, PHD,†
Panagiotis Korantzopoulos, MD, PHD‡
Tianjin, People’s Republic of China; and Ioannina, Greece
Objectives We conducted a systematic review and meta-analysis of observational studies to examine the association be-
tween baseline C-reactive protein (CRP) levels and the recurrence of atrial fibrillation (AF) after successful elec-
trical cardioversion (EC).
Background Current evidence links AF to the inflammatory state. Inflammatory indexes such as CRP have been related to the
development and persistence of AF. However, inconsistent results have been published with regard to the role of
CRP in predicting sinus rhythm maintenance after successful EC.
Methods Using PubMed, the Cochrane clinical trials database, and EMBASE, we searched for literature published June
2006 or earlier. In addition, a manual search was performed using all review articles on this topic, reference
lists of papers, and abstracts from conference reports. Of the 225 initially identified studies, 7 prospective obser-
vational studies with 420 patients (229 with and 191 without AF relapse) were finally analyzed.
Results Overall, baseline CRP levels were greater in patients with AF recurrence. The standardized mean difference in
the CRP levels between the patients with, and those without AF was 0.35 units (95% confidence interval 0.01 to
0.69); test for overall effect z-score  2.00 (p  0.05). The heterogeneity test showed that there were significant
differences between individual studies (p  0.02; I2  60.2%). Further analysis revealed that differences be-
tween the CRP assays possibly account for this heterogeneity.
Conclusions Our meta-analysis suggests that increased CRP levels are associated with greater risk of AF recurrence, al-
though there was significant heterogeneity across the studies. The use of CRP levels in predicting sinus rhythm
maintenance appears promising but requires further study. (J Am Coll Cardiol 2007;49:1642–8) © 2007 by
the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.12.042(
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(trial fibrillation (AF) is the most common arrhythmia
ncountered in clinical practice, and its prevalence has
ncreased during the past few decades (1,2). Because AF is
ndependently associated with increased cardiovascular mor-
See page 1649
idity and mortality, it unequivocally represents a major
ublic health problem (1,2). Although control of the ven-
ricular response is an acceptable treatment in certain
ubgroups of patients, restoration and maintenance of sinus
hythm remains the preferred strategy in many patients
rom the *Department of Cardiology, Tianjin Institute of Cardiology, Second
ospital of Tianjin Medical University, Tianjin, People’s Republic of China;
College of Graduate Students, Tianjin Medical University, Tianjin, People’s
epublic of China; and the ‡Department of Cardiology, “G. Hatzikosta” General
ospital of Ioannina, Ioannina, Greece.w
Manuscript received October 24, 2006; revised manuscript received December 4,
006, accepted December 19, 2006.2,3). This strategy offers several potential benefits, such as
he prevention of electrical and structural remodeling of the
tria, improved hemodynamic function, amelioration of
ymptoms, and improvement in the quality of life (3,4).
lthough some recent studies indicate increased efficacy of
harmacological cardioversion using combination therapy
5,6), electrical cardioversion (EC) is the most commonly
sed method for sinus rhythm restoration in patients with
ersistent AF.
Despite the use of antiarrhythmic agents for sinus rhythm
aintenance, a considerable proportion of patients relapse to
F (1,2). It is generally believed that these relapses are
ssociated with older age, atrial dilation, and long duration of
he arrhythmia. This tendency to become sustained over time
annot be easily managed, representing a challenging thera-
eutic problem. An increasing body of evidence suggests the
ole of inflammation in the genesis and perpetuation of AF
7–10). The possibility that the association of inflammation
ith AF could be examined with the use of C-reactive protein
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April 17, 2007:1642–8 C-Reactive Protein and Atrial FibrillationCRP) has captured the attention of many researchers (11). In
he past few years, several studies have investigated the asso-
iation between baseline CRP levels and AF recurrence rates
fter successful EC. Although some of these studies indicated
positive association between CRP levels and AF recurrence
12–15), others failed to demonstrate such a relationship
16–18). Therefore, we conducted a systematic review of the
vidence obtained from observational studies to evaluate the
ssociation between CRP levels before cardioversion and AF
ecurrence rates after successful EC.
ethods
eta-analyses of observational studies present particular
hallenges because of inherent biases and differences in
tudy designs. Consequently, we performed this analysis
ccording to the guidelines of the Meta-analysis of Obser-
ational Studies in Epidemiology Group (MOOSE) (19).
nclusion criteria. Studies were considered eligible for this
eview if they met the following criteria: 1) they were of a
rospective observational study design; 2) they evaluated the
otential association between CRP levels before cardiover-
ion and AF recurrence after successful EC; 3) they used AF
ecurrence rates as an outcome; and 4) the period of follow-up
as no shorter than 1 week. We included published and
npublished studies without language restriction.
earch strategies. We carefully searched MEDLINE
January 1966 to June 2006), EMBASE (January 1980 to
une 2006), and the Cochrane Controlled Trials Register
Cochrane Library Issue 2, 2006) databases to identify
elevant studies. We used the following keywords:
C-reactive protein,” “inflammation,” and “atrial fibrilla-
ion.” Titles and abstracts as well as the reference lists of all
f the identified reports were examined independently by 2
eviewers (T.L. and L.L.) to include potentially relevant
tudies. The 2 reviewers agreed on the inclusion/exclusion
tatus in 92% of the reviewed studies. Disagreements were
esolved by discussion or consensus of a third reviewer
G.L.). Additionally, a manual search was conducted using
ll review articles on this topic, bibliographies of original
apers, and abstracts of the scientific sessions of the Amer-
can College of Cardiology, the American Heart Associa-
ion, the European Society of Cardiology, and the North
merican Society of Pacing and Electrophysiology (Heart
hythm Society) during the past 5 years.
uality assessment and data extraction. Because quality
coring is controversial in meta-analyses of observational
tudies, we systematically assessed several key points of
tudy quality. Two reviewers (T.L. and L.L.) independently
ppraised each article included in our analysis according to
critical review checklist of the Dutch Cochrane Centre
hich was proposed by MOOSE (19). The key points of
his checklist are as follows: 1) clear definition of study
opulation; 2) clear definition of outcomes and outcome
ssessment; 3) independent assessment of outcome param-
ters; 4) sufficient duration of follow-up; 5) no selective loss puring follow-up; and 6) impor-
ant confounders and prognostic
actors identified. If a study did
ot clearly mention one of these
ey points, we considered that it
ad not been performed and,
onsequently, that there was a
ossibility for underestimation of
he reported characteristics.
Two blinded reviewers (T.L.
nd L.L.) independently performed data extraction using a
tandard data extraction form to determine eligibility for
nclusion and extract data. The extracted data elements of this
eview included: 1) publication details: first author’s last name,
ublication year, and origin of the studied population; 2) study
esign; 3) characteristics of the studied population: sample size,
ge, gender, diagnoses, methods of CRP measurement, dura-
ion of follow-up, number of withdrawals, and dropouts; 4)
nd point evaluation (methods of AF detection); 5) rates of AF
ecurrence and sinus rhythm maintenance during the
ollow-up period, and means and SDs of CRP in each group.
isagreements were resolved by consensus with a third re-
iewer (G.L.).
If the study provided medians and interquartile ranges
nstead of means and SDs, we imputed the means and SDs
s described by Hozo et al. (20). We calculated the lower
nd upper ends of the range by multiplying the difference
etween the median and upper and lower ends of the
nterquartile range by 2 and adding or subtracting the
roduct from the median, respectively.
tatistical analysis. To accommodate differences in the
ay in which CRP measured and reported across various
aboratories, the absolute CRP levels were converted into a
ommon unit by calculating standardized effect sizes. Stan-
ardized effect sizes were derived by dividing the mean
ifference of CRP levels in AF recurrence and no AF
ecurrence groups of each study by its SD. We used the I2
tatistic to measure the extent of inconsistency among the
esults and tested the heterogeneity using Cochran’s Q test.
ecause this test has poor power in the case of few studies,
e considered both the presence of significant heterogeneity
t the 10% level of significance and values of I2 exceeding
6% as an indicator of significant heterogeneity (21), so a
ooled effect was calculated with a random-effects model
hich was used to take into account within-study and
etween-study variance, otherwise, with a fixed-effects
odel. To explore sources of heterogeneity, we performed
everal sensitivity and subgroup analyses. Publication bias
as evaluated using the funnel plot. All analyses were
onducted using Review Manager version 4.2 (Revman,
he Cochrane Collaboration, Oxford, United Kingdom).
esults
wo hundred twenty-five records were identified by the
Abbreviations
and Acronyms
AF  atrial fibrillation
CRP  C-reactive protein
EC  electrical
cardioversion
ELISA  enzyme-linked
immunosorbent assayrimary literature search. However, after screening the titles
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C-Reactive Protein and Atrial Fibrillation April 17, 2007:1642–8nd abstracts, 194 studies were excluded because they were
ither laboratory studies, review articles, or irrelevant to the
urrent analysis. Of the 31 reports selected for detailed evalu-
tion, 17 studies did not assess the AF patients who underwent
C, 2 studies were randomized control trials that evaluated
rug interventions on AF prevention after successful EC
22,23), and 2 further studies were excluded because they were
reliminary abstracts followed by subsequent full manuscripts.
ne study was excluded because a portion of the studied
atients followed after unsuccessful EC (24), whereas in
nother one the follow-up period was too short (25). Finally, in
ne additional study, CRP levels were not reported in the AF
ecurrence group (26). Consequently, 7 prospective observa-
ional cohort studies (12–18) finally were included in our
eta-analysis (Fig. 1). Overall, there were 420 patients in-
olved in our review: 229 in the AF recurrence group, and 191
n the no AF recurrence group. The follow-up period varied
etween 7 and 140 days. The quality assessment of the 7
tudies is presented in Table 1, whereas the characteristics of
ach study are depicted in Table 2.
Figure 1 Flow Diagram of the Trial Selection Process
AF  atrial fibrillation; CRP  C-reactive protein; EC  electrical cardioversion; RC
ssessment of the Quality of the 7 Included Studies
Table 1 Assessment of the Quality of the 7 Included Studies
Korantzopoulos
et al. (16) e
Clear definition of study population? Yes
Clear definition of outcomes and outcome assessment? Yes
Independent assessment of outcome parameters? Yes
Sufficient duration of follow-up? Yes
No selective loss during follow-up? Yes
Important confounders and prognostic factors identified? No/A  not available.Four studies showed that patients with AF recurrence
ad greater CRP levels than those without (12–15), whereas
RP levels did not show significant difference between the
groups in 3 other studies (16–18). Overall, CRP concen-
ration was greater in patients with AF recurrence. The
tandardized mean difference in the CRP levels between the
atients with, and those without AF recurrence was 0.35
nits (95% confidence interval 0.01 to 0.69) (Fig. 2), and the
-score for overall effect was 2.00 (p  0.05). The hetero-
eneity test showed that there were significant differences
etween individual studies (p  0.02; I2  60.2%). We
ubsequently performed sensitivity and subgroup analyses to
nd the origin of this heterogeneity. After removing 1 study
hat enrolled patients with atrial flutter or 1 study that had
he shortest follow-up period, the analysis did not find a
ignificant influence on the results. Of note, after excluding
he study by Zarauza et al. (15), which used a high-
ensitivity C-reactive protein enzyme-linked immunosor-
ent assay (ELISA) to measure CRP levels, heterogeneity
est showed that there were no significant differences be-
andomized control trials.
zi
12)
Malouf
et al. (13)
Zarauza
et al. (15)
Watanabe
et al. (14)
Cosgrave
et al. (17)
Buob
et al. (18)
Yes Yes Yes Yes Yes
Yes No Yes Yes Yes
N/A N/A N/A N/A N/A
Yes Yes Yes Yes Yes
Yes Yes Yes Yes Yes
Yes Yes Yes Yes NoTs  rWan
t al. (
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April 17, 2007:1642–8 C-Reactive Protein and Atrial Fibrillationween the remaining 6 studies (p  0.32; I2  14.1%),
hereas the standardised mean difference in the CRP levels
etween the patients with and without AF recurrence was
.23 units (95% CI 0.02 to 0.45); the z-score for overall
ffect was 2.11 (p  0.03). Therefore, differences in the
RP assay may be a possible source of heterogeneity.
In addition, we performed a prespecified subgroup anal-
sis of studies with a follow-up period of at least 2 months
nd those of 2 months. The proportion of total variation
cross studies that was due to heterogeneity rather than
hance was I2  58.4% (p  0.09) in the 3 studies with a
ollow-up period of at least 2 months, and I2  69.5% (p 
.02) in the 4 studies with a follow-up period of 2
onths. Thus, it did not explain the cause of heterogeneity
n our results. The funnel plot (Fig. 3) suggested that there
as little publication bias, although the small number of
tudies made it difficult to interpret.
iscussion
n this meta-analysis of 7 prospective observational studies,
e demonstrated that increased baseline CRP levels are
ssociated with greater risk for AF recurrence after success-
ul external EC, although there was significant heterogene-
ty across the studies. After excluding a study that caused
eterogeneity (15), the overall effect of CRP elevation on
F relapse was more prominent (z-score 2.11, p 0.03).
eeping in mind the clinical importance of sinus rhythm
aintenance after successful EC, as well as the inconsistent
ublished results regarding the effect of inflammation in this
etting, this meta-analysis is of special importance.
The pathophysiological mechanism that underlies the
evelopment of electrophysiological and structural substrate
hat promotes AF maintenance and recurrence has been
amed “atrial remodelling” (27). Currently, there is an
ncreasing research interest on the role of inflammation and
xidative stress in the pathophysiology of AF (7–11,28). It
as also been speculated that these processes are interrelated
nd contribute to the atrial remodeling (7,9,10,28). Re-
arkably, an increasing body of evidence links AF to the
nflammatory state (9,10). Inflammatory indexes, mainly
RP, have been related to future AF development, AF
ecurrences after cardioversion, and to the associated pro-
hrombotic state (9,10). Moreover, the persistence of AF
as been associated with the degree of inflammation (29).
lso, several pharmacological approaches with nonchannel
locking drugs that, among other pleiotropic, have anti-
nflammatory properties, show favorable effects on AF
10,22,28,30,31). These include inhibitors of the renin-
ngiotensin system, statins, dietary antioxidants, corticoste-
oids, n-3 fatty acids, and others (10,22,28,30,31). Dernellis
nd Panaretou (32) indicated the efficacy of corticosteroid
reatment in preventing recurrent AF but, more interest-
ngly, they demonstrated that corticosteroid treatment sig-nificantly reduced the CRP levels from the first month,
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C-Reactive Protein and Atrial Fibrillation April 17, 2007:1642–8hereas a strong relationship between CRP increase and the
isk of AF recurrence was observed (32).
Despite the aforementioned evidence, it is not yet clear
hether inflammation is a primary pathogenetic event or a
onsequence of AF. However, there is a possibility that both
rocesses feeding each other leading to a vicious cycle. It
ould be hypothesized that ongoing inflammation can
nhance atrial remodeling, thus promoting AF recurrence
13). This hypothesis is supported by the temporal relation
f increases in inflammatory indexes (CRP, complement,
hite blood cell count) after cardiac surgery and the onset of
ostoperative AF (33,34). Moreover, elevated CRP levels
ave been reported very early (even in the first 24 h) after
F initiation, suggesting that inflammation may promote
F persistence (29). Very recently, it was demonstrated that
n patients with acute myocardial infarction there seems to
e an independent positive association between elevated
Figure 2 Comparison of CRP Levels Between AF Recurrence an
AF  atrial fibrillation; CI  confidence interval; CRP  C-reactive protein; SMD 
Figure 3 Funnel Plot of the Meta-Analysis
Review: C-reactive protein and recurrence of AF after successful electrical car-
dioversion. Comparison: 01 AF recurrence versus no AF recurrence. Outcome:
01 AF recurrence. SE  standard error; other abbreviations as in Figure 2.mRP and new-onset AF suggesting a pathogenetic role for
nflammation (35,36).
However, if inflammation simply accompanies atrial re-
odeling, then the restoration of sinus rhythm might lead
o the gradual decrease of the inflammatory markers,
hereas failure of the reverse atrial remodeling and the
mpeding recurrence of the arrhythmia might be indicated
y the abolishment of this decrease. Of note, some investi-
ators claim that the abnormal inflammatory state may be
elated, at least in part, to other comorbidities. Regardless of
he presence or not of a causal relationship, the study of
aseline CRP levels and/or their variation after cardiover-
ion may provide significant prognostic information regard-
ng sinus rhythm maintenance (16,37). C-reactive protein is
n acute-phase protein that has been emerged as a reliable
iomarker of systemic inflammation in several cardiovascu-
ar diseases (11,38). Importantly, CRP is an easily deter-
ined marker in everyday clinical practice worldwide and
hus, successive measurements can be easily performed.
Undoubtedly, a unique basal measurement of CRP before
F cardioversion cannot reflect the inflammatory process
hroughout time. To date, only 1 small study examined the
ime-course of the inflammatory indexes after cardioversion
16). In this study, serial measurements of CRP, fibrinogen,
nd white blood cell count were performed on the first,
hird, and seventh day after cardioversion. It was demon-
trated that fibrinogen levels increased significantly in pa-
ients who relapsed to AF but remained stable in patients
ho remained in sinus rhythm. In the latter patients, CRP
alues tended to decrease after cardioversion, but white
lood cell count was significantly lower on the seventh day
ompared with baseline values (16). It could be therefore
peculated that the variation of inflammatory indexes after
C of persistent AF might have prognostic implications
16). Moreover, successive measurement of simple inflam-
AF Recurrence Groups in the 7 Included Studies
rdized mean difference.d No
standaatory indexes might be clinically useful in monitoring the
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April 17, 2007:1642–8 C-Reactive Protein and Atrial Fibrillationffectiveness of various anti-inflammatory treatments in
atients with AF (16). In 2 further studies, CRP levels were
etermined only once after cardioversion. Cosgrave et al.
17) measured CRP at baseline and 8 weeks after cardio-
ersion and found no differences in patients who recurred to
F as well as in those who remained in sinus rhythm.
imilar results also were obtained by Buob et al. (18) by
easuring CRP at baseline and 1 month after EC.
In our analysis, we included 1 study that had a short
ollow-up period of just 1 week (16). We consider that this
ime interval is sufficient and critical because the greatest
ncidence of AF recurrence occurs during the first days after
ardioversion. Tieleman et al. (39) have demonstrated that
he recurrence rate can reach the level of 35% in the first 5
ays after cardioversion. It also has been suggested that
trial electrical remodeling resolves during the first days
fter cardioversion of persistent AF and may be related to
arly recurrence rates (39). In addition, as already men-
ioned, the removal of this study from the analysis did not
ave a significant impact on the results.
When between-study variation cannot be explained by
hance, exploration of the reasons for heterogeneity rather
han derivation of a single summary estimate have been
merged as the main goal of a meta-analysis (40). The
eterogeneity test of our analysis showed that there were
ignificant differences between individual studies. Subse-
uently, sensitivity and subgroup analyses were performed
o investigate the underlying causes; differences between the
easurements of CRP in the studies may be a possible
ource of heterogeneity. In the aforementioned 7 studies, in
of them (12–14,16–18) researchers used immunoneph-
lometric assay to measure CRP concentrations, and only in
study (15) did researchers assess CRP by using ELISA.
he ELISA methodology is used primarily for research
urposes and is not ideal for routine use in highly automated
linical laboratories (41). Recently, latex-enhanced immu-
onephelometric method and the immunoturbidimetric
ssay have been evaluated and validated clinically (42).
hese assays possess improved sensitivity and precision at
ow concentrations of CRP. Finally, we demonstrated that
nrolment of patients with atrial flutter and short follow-up
uration did not explain the aforementioned heterogeneity.
tudy limitations. We feel that our study adds to the
urrent understanding of the association between inflam-
ation and AF recurrence. However, some potential limi-
ations may be apparent. Firstly, our analysis is based on
bservational studies and may be subjected to the potential
iases of such studies. Therefore, our results should be
nterpreted cautiously. Second, converting non-normally
istributed statistics (median and range) to normally dis-
ributed statistics (mean and SD) may be a cause of bias in
ur analysis. Third, because the number of studies in our
eta-analysis was small, we cannot exclude the possibility of
ublication bias, although our funnel plot showed that
ublication bias is unlikely, (43). Fourth, although most of
he studies attempted to control the potential confounders,he degree to which this was accomplished varied among
hem. Fifth, no study of those included in the meta-analysis
rovided information regarding the inflammatory state be-
ore the beginning of AF. Finally, methods of AF detection
ere different between the trials and therefore some asymp-
omatic episodes of AF may be overlooked.
onclusions
n conclusion, our meta-analysis suggests that increased
aseline CRP levels are associated with higher risk of AF
ecurrence after successful EC, although there was a signif-
cant heterogeneity across the studies. Our results need to be
onfirmed by larger well-designed randomized studies with
onger follow-up periods. The merit of successive measure-
ent of CRP after cardioversion, as well as the examination
f the role of other inflammatory markers such as white
lood cell count, and interleukin-6, constitutes a subject for
uture research.
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